Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study.
D. E. Rathkopf
No relevant relationships to disclose
D. C. Danila
No relevant relationships to disclose
M. J. Morris
No relevant relationships to disclose
S. F. Slovin
No relevant relationships to disclose
L. S. Borwick
No relevant relationships to disclose
L. Momen
No relevant relationships to disclose
T. Curley
No relevant relationships to disclose
G. Arauz
No relevant relationships to disclose
S. M. Larson
No relevant relationships to disclose
M. Fleisher
No relevant relationships to disclose
N. Rosen
No relevant relationships to disclose
H. I. Scher
No relevant relationships to disclose